Long-acting aripiprazole injection introduced in Korea

Otsuka's Abilify Asimtufai, a long-acting injectable aripiprazole for schizophrenia and bipolar disorder, approved in Korea. It allows bimonthly dosing, improving on previous monthly injections.

Fangzhou launches Otsuka's leukemia drug Ponatinib

Fangzhou Inc. has launched Otsuka's third-generation leukemia drug Ponatinib on its platform, expanding access to this advanced treatment.

Curient competes in ADC market with proprietary platform

Curient is gaining attention with its next-generation ADC platform technology, aiming to compete globally in the rapidly growing ADC market for cancer treatment.